- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.06. | Gain Therapeutics, Inc.: Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit | 2 | GlobeNewswire (USA) | ||
| 27.05. | Oppenheimer bestätigt "Outperform" für Gain Therapeutics | 4 | Investing.com Deutsch | ||
| 27.05. | Gain Therapeutics stock maintained at Outperform by Oppenheimer | 1 | Investing.com | ||
| 26.05. | Gain Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.05. | Gain Therapeutics presents phase 1b data on Parkinson's drug | 3 | Investing.com | ||
| GAIN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.05. | Gain Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.05. | Gain Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.05. | Gain Therapeutics übertrifft Verlustprognosen - Aktie legt zu | 3 | Investing.com Deutsch | ||
| 11.05. | Gain Therapeutics GAAP EPS of -$0.13 beats by $0.01 | 2 | Seeking Alpha | ||
| 11.05. | Gain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update | 273 | GlobeNewswire (Europe) | BETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the... ► Artikel lesen | |
| 24.04. | Gain Therapeutics, Inc.: Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026 | 3 | GlobeNewswire (USA) | ||
| 26.03. | Gain Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | Gain Therapeutics GAAP EPS of -$0.61 beats by $0.03 | 2 | Seeking Alpha | ||
| 18.03. | Gain Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.03. | Gain Therapeutics reports biomarker data from Parkinson's trial | 1 | Investing.com | ||
| 18.03. | Gain Therapeutics legt vielversprechende Biomarker-Daten aus Parkinson-Studie vor | 18 | Investing.com Deutsch | ||
| 18.03. | Gain Therapeutics, Inc.: Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 | 2 | GlobeNewswire (USA) | ||
| 03.02. | Gain Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.01. | Gain Therapeutics reports 81% reduction in Parkinson's biomarker | 13 | Investing.com |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 0,969 | +0,68 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| INFLARX | 1,687 | -0,24 % | InflaRx NV im Höhenflug: Was hinter dem Kursanstieg wirklich steckt - Was ich konkret unternommen habe! | ||
| INTELLIA THERAPEUTICS | 14,120 | -3,42 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| IBIO | 1,443 | -1,30 % | iBio, Inc.: iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity | IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition First-in-human study of IBIO-600 to evaluate safety,... ► Artikel lesen | |
| IMMUNITYBIO | 7,590 | 0,00 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 8,200 | -1,97 % | Immatics N.V. - S-8, Securities to be offered to employees in employee benefit plans | ||
| MANNKIND | 3,577 | 0,00 % | MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza in Youth with Newly-Diagnosed T1D | Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE... ► Artikel lesen | |
| IMMUNIC | 13,115 | -1,83 % | EQS-News: Immunic AG: Immunic to Participate in Investor, Industry and Scientific Conferences in June | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor, Industry and Scientific Conferences in June
10.06.2026 / 12:30 CET/CEST
The issuer is... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 3,740 | +0,54 % | Iovance Biotherapeutics, Inc.: Iovance's Amtagvi (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia | First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE... ► Artikel lesen | |
| GUARDANT HEALTH | 129,74 | -1,08 % | Bernstein upgrades Guardant Health stock rating on FDA approval impact | ||
| MOLECULIN BIOTECH | 3,400 | +3,98 % | Moleculin Biotech, Inc.: Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial | Early blinded results show 40% composite complete remission rate across difficult-to-treat AML patient population in MIRACLE Trial First interim unblinding expected in June 2026 following 45 subject... ► Artikel lesen | |
| INSMED | 91,50 | +0,73 % | EQS-News: EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis | EQS-News: EMBARC
/ Key word(s): Study/Letter of Intent
EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification... ► Artikel lesen | |
| GENPREX | 0,504 | +1,82 % | Genprex, Inc.: Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer | Patent Covers Acclaim-3 Clinical Trials Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq®
AUSTIN, Texas, June 22, 2026 /PRNewswire/ -- Genprex, Inc.... ► Artikel lesen | |
| MACROGENICS | 4,320 | +2,37 % | MacroGenics, Inc.: MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD Approval | ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment... ► Artikel lesen | |
| BIOAGE LABS | 20,640 | -0,86 % | BioAge Labs: NBC-Komplettexit nach fast +500% Rendite | Was für eine Erfolgsstory: Nachdem die BioAge-Labs-Aktie im Januar bereits eine Performance von bis zu +449% auf den ursprünglichen Empfehlungskurs erreicht hatte, ist der No Brainer Club nun auch mit... ► Artikel lesen |
Das Unternehmen GAIN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,005 (-0,29 %) liegt der Kurs bei 1,745 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GAIN THERAPEUTICS INC finden Sie auf Wallstreet Online.